British Columbia Adds Insulins To Its Biosimilar Switching Policy
Canadian Province Says Patients Have Six Months To Make The Transition
Executive Summary
Patients taking Humalog and NovoRapid will have six months to switch to their biosimilar equivalents after British Columbia added the rapid-acting insulins to its biosimilar switching policy.
You may also be interested in...
British Columbia Adds Three Anti-Clotting Biosimilars To PharmaCare
British Columbia has added three new biosimilar versions of the anti-clotting drug enoxaparin to PharmaCare, including Redesca, Noromby and Inclunox. The move comes after the Canadian province recently included additional biosimilars in its switching program.
Health Canada Ponders UK Model On Easing Biosimilar Study Requirements
Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.
Biosimilars Canada Boss Calls For Ontario Switching Policy
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.